中山医科大学（现中山大学医学院）临床医学学士、中山大学附属第一医院消化科医学博士、美国UCLA教学医院Cedar-Sinai 医疗中心博士后、美国西南大学医学院炎症性肠病中心访问学者。 社会兼职： 中华医学会消化病学分会炎症性肠病学组副组长 中国炎症性肠病诊治质控评估中心秘书长 亚洲炎症性肠病协会(AOCC) 临床研究学组主任 广东省医师协会消化内镜分会副主任委员 在国内外学术期刊共发表学术论文近百篇，参编专著8部。多次在大型国际国内学术会议上进行主题演讲。 代表性论著： 1. Predicting Factors of Long-term Outcome of Gastrointestinal Behcet’s Disease: A Chinese Retrospective Study. Clin Ther. 2024 Jan 30:S0149-2918(24)00005-5. doi: 10.1016/j.clinthera.2023.12.012. 2. Role of Colchicine in Different Clinical Phenotypes of Behcet Disease. Clin Ther. 2023 Feb;45(2):162-176. doi: 10.1016/j.clinthera.2023.01.004. Epub 2023 Feb 1. Erratum in: Clin Ther. 2023 Sep;45(9):923. PMID: 36732153. 3. Mucosal Healing and Quality of Life in Therapeutic Goals of Ulcerative Colitis: Occurrence and Related Factors of Functional Bowel Disorders. Therap Adv Gastroenterol 2022:17562848221092597.doi: 10.1177/17562848221092597 4. Multi-omics Analysis of Western-style Diet Increased Susceptibility to Experimental Inflammatory Bowel Disease. J Inflamm Res 2022 Apr 21;15:2523-2537 5. IBD合并风湿免疫病诊治策略(综述)。中华炎性肠病杂志 2021 6. 狭窄型克罗恩病的诊断与治疗进展（综述）。中国医学前沿杂志2021 7. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide for the treatment of immune-related bowel disease. J Dig Dis. 2020 Feb;21(2):98-103. 8. Epstein-Barr virus status on clinicopathologic characteristics and clinical outcomes in ulcerative colitis：a study on high incidence area of the viral infection. Therapeutic Advances in Gastroenterology 2020 9. Which Long Noncoding RNAs and Circular RNAs Contribute to Inflammatory Bowel Disease?（综述） Cell death and disease.2020 Jun 15;11(6):456 10. 沙利度胺治疗难治性克罗恩病的长期疗效及安全性分析. 中华内科杂志, 2020, 59 (6). 11. Development and validation of a novel diagnostic nomogram to differentiate between Intestinal tuberculosis and Crohn’s Disease: A 6-year prospective multi-center study. Am J Gastroenterol 2019 Mar;114(3):490-499 12. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therap Adv Gastroenterol. 2017 May;10(5):397-406 13. The value of empiric anti-tuberculosis therapy in the differential diagnosis between intestinal tuberculosis and Crohn’s disease in China. Int J Clin Exp Med. 2016;9(6):9278-85.( IF: 1.277) 14. Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China. Int J Clin Exp Med. 2015;8(5):8078-85.( IF: 1.277) 15. 难治性克罗恩病的临床特征及影响因素分析. 中华医学杂志 2014；94(38): 2982-2987 16. 甲氨蝶呤治疗难治性克罗恩病的疗效及安全性分析. 中华内科杂志. 2014; 53(3): 188-192 17. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease. J Dig Dis. 2013; 14(12): 662-669. 18. PCR法检测分枝杆菌DNA在鉴别克罗恩病与肠结核中的价值. 中国病理生理杂志. 2013; 29 (1): 188-192 19. 回结肠克罗恩病与肠结核临床及内镜特征比较. 中华消化内镜杂志. 2012; 26(6): 48-52 20. 沙利度胺治疗克罗恩病的研究进展（综述）. 胃肠病学 2012; 9: 570-572 21. 专家笔谈：克罗恩病的诊断与鉴别诊断. 现代消化及介入诊疗 2010; 15(4): 236-240 22. 专家笔谈：炎症性肠病的内科治疗. 实用医学杂志 2003;5(19):453-455